EU committee approves Akcea-Ionis drug for rare genetic disease [Reuters]
AKCEA THERAPEUTICS (AKCA)
Last akcea therapeutics earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akceatx.com/media-investors/press-releases
Company Research
Source: Reuters
EU committee approves Akcea-Ionis drug for rare genetic disease March 1 (Reuters) - An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood. The nod from EMA’s Committee for Medicinal Products for Human Use is a shot in the arm for the companies after their shares plunged in August when the U.S. Food and Drug Administration declined to approve the drug, Waylivra. Waylivra is designed to treat familial chylomicronemia syndrome, a rare genetic disorder that can cause a potential fatal inflammation of the pancreas. Regulators have in the past raised safety concerns such as low platelet count associated with the drug, but there is a lack of available treatments for the condition. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta) Our Standards: The Thomson Reuters Trust
Show less
Read more
Impact Snapshot
Event Time:
AKCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKCA alerts
High impacting AKCEA THERAPEUTICS news events
Weekly update
A roundup of the hottest topics